Common Contracts
3 similar Lock-Up Agreement contracts by 180 Life Sciences Corp., Feldmann Marc, KBL Merger Corp. Iv
LOCK-UP AGREEMENTLock-Up Agreement • November 18th, 2020 • Feldmann Marc • Pharmaceutical preparations • Delaware
This Lock-Up Agreement supersedes any previous lock-up agreements entered into between the undersigned signatory and KBL.
FORM OF LOCK-UP AGREEMENTLock-Up Agreement • November 12th, 2020 • 180 Life Sciences Corp. • Blank checks • Delaware
The undersigned signatory of this lock-up agreement (this “Lock-Up Agreement”) understands that KBL Merger Corp. IV, a Delaware corporation (“KBL”) proposes to enter into a Business Combination Agreement (as the same may be amended from time to time, the “Business Combination Agreement”) with KBL Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of KBL (“Merger Sub”), 180 Life Sciences Corp (f/k/a CannBioRx Life Sciences Corp.), a Delaware corporation (the “Company”), Katexco Pharmaceuticals Corp., a British Columbia corporation (“Katexco”), CannBioRex Pharmaceuticals Corp., a British Columbia corporation (“CBR Pharma”), 180 Therapeutics LP, a Delaware limited partnership (“180” and together with Katexco and CBR Pharma, the “Company Subsidiaries”), and Lawrence Pemble, in his capacity as representative of the stockholders of the Company and the Company Subsidiaries which provides, among other things, for the merger of Merger Sub with and into the Company, with the
FORM OF LOCK-UP AGREEMENTLock-Up Agreement • July 26th, 2019 • KBL Merger Corp. Iv • Blank checks • Delaware
The undersigned signatory of this lock-up agreement (this “Lock-Up Agreement”) understands that KBL Merger Corp. IV, a Delaware corporation (“KBL”) proposes to enter into a Business Combination Agreement (as the same may be amended from time to time, the “Business Combination Agreement”) with KBL Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of KBL (“Merger Sub”), CannBioRx Life Sciences Corp., a Delaware corporation (the “Company”), Katexco Pharmaceuticals Corp., a British Columbia corporation (“Katexco”), CannBioRex Pharmaceuticals Corp., a British Columbia corporation (“CBR Pharma”), 180 Therapeutics LP, a Delaware limited partnership (“180” and together with Katexco and CBR Pharma, the “Company Subsidiaries”), and Lawrence Pemble, in his capacity as representative of the stockholders of the Company and the Company Subsidiaries which provides, among other things, for the merger of Merger Sub with and into the Company, with the Company continuing as the survi
